SubHero Banner

Xarelto® (rivaroxaban) – Expanded indication

August 24, 2021 - Janssen announced the FDA approval of Xarelto (rivaroxaban), in combination with aspirin, to reduce the risk of major thrombotic vascular events (myocardial infarction, ischemic stroke, acute limb ischemia, and major amputation of a vascular etiology) in patients with peripheral artery disease (PAD), including patients who have recently undergone a lower extremity revascularization procedure due to symptomatic PAD.

Download PDF